Stock Transcript: VeroScience supports DeFronzo’s research

VeroScience LLC, is pleased to announce that independent research conducted by Dr. Ralph DeFronzo and his team at UT Health Science Center at San Antonio (“Health Science Center“) has continued to delineate metabolic targets of VeroScience’s Cycloset® in reducing hyperglycemia in type 2 diabetes mellitus (T2DM) patients. The study has also identified positive influences of the therapy upon vascular risk factors of cardiovascular disease.

Read the full story at Stock Transcript

Share This Article!